Thomas Weisel Maintains 'Buy' on Digene

Analyst David Lewis sees 54% revenue growth in 2004 for the company with its newly-approved cervical cancer test

Thomas Weisel reiterates buy on Digene (DIGE ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.